SCHEMBL17100349

SCHEMBL17100349

COCOc1ccc(Br)cc1C(O)c1ccsc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
CYP2C19 P33261 2/20 0.33
TSHR P16473 2/20 0.33
HIF1A Q16665 1/20 0.33
CYP2C9 P11712 1/20 0.33
ELANE P08246 2/20 0.32
HPGD P15428 1/20 0.32
CYSLTR2 Q9NS75 1/20 0.31
CYSLTR1 Q9Y271 1/20 0.31
HTR1A P08908 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KMT2A Q03164 1/20 0.31
LMNA P02545 2/20 0.30
MAPT P10636 1/20 0.30
PPARG P37231 1/20 0.30
GFER P55789 1/20 0.30
NCOA2 Q15596 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100358 0.82 HTR1A (0.40) HTR1ATDP1PPARGSLC6A2SLC6A4
SCHEMBL282475 0.73 ALDH1A1 (0.47) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL23320401 0.71 LMNA (0.39) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL17100461 0.70 PTGDR2 (0.48) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL8815713 0.70 TSHR (0.34) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL8710227 0.70 CYP3A4 (0.36) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL31041181 0.70 TSHR (0.37) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL28009643 0.68 TSHR (0.41) CYP3A4CYP2D6CYP2C19TSHRHIF1A
SCHEMBL5752891 0.68 HPGD (0.43) CYP2D6HPGDKDM4EKMT2ALMNA
SCHEMBL128396 0.67 ALOX15 (0.42) CYP3A4CYP2D6CYP2C19TSHRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3119760-A1 PIPERIDINE-DIONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-01-25 EP disclosed
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2017-01-05 US disclosed
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2017-01-05 US disclosed
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2017-01-05 US disclosed
WO-2015140133-A1 PIPERIDINE-DIONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-09-24 WO disclosed
WO-2015142903-A2 METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2015-09-24 WO disclosed
WO-2015140133-A1 PIPERIDINE-DIONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-09-24 WO disclosed
WO-2015142903-A2 METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES DRD4, ADORA1, ADORA3 CYP3A4 122/4885CYP2D6 346/4885CYP2C19 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.